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Abstract: To compare the value of cytokeratin fragment 21-1
(CYFRA 21-1) concentration in the fine-needle biopsy aspirates (fine
needle aspirate [FNA] CYFRA 21-1) with cytopathology of fine-needle
aspiration biopsy (FNA cytology) and to assess whether CYFRA 21-1
concentrations from ultrasound-guided fine-needle aspiration biopsy
(US-FNAB) specimens (FNA CYFRA 21-1) is not inferior to FNA
cytology in the diagnosis of axillary lymph node (ALN) metastasis of
breast cancer patients.
This study received institutional review board approval, and written
informed consent was obtained from all patients. US-FNAB was
performed in 373 ALNs from 358 patients with invasive breast cancer.
Concentrations of CYFRA 21-1 were measured from washouts of the
syringe used during US-FNAB (FNA CYFRA 21-1), and ALN metas-
tasis was determined using a cutoff value of 1.93 ng/mL. FNA cytology,
intraoperative sentinel lymph node biopsy, and surgical pathology
results were reviewed and analyzed. The noninferiority margin for
the difference in accuracies between FNA cytology and FNA CYFRA
21-1 was set as 5%.
Among 373 ALNs, 136 (36.5%) were benign, and 237 (63.5%) were
metastatic. The mean FNA CYFRA 21-1 was significantly higher in
metastatic ALNs compared to that in benign ALNs (P¼ 0.001). For the
diagnosis of ALN metastasis, the sensitivity, specificity, positive pre-
dictive value, negative predictive value, and accuracy of FNA CYFRA
21-1 (cutoff value 1.93 ng/mL) were not significantly different from
those of FNA cytology (P> 0.05). FNACYFRA 21-1 reached statistical
noninferiority to FNA cytology in terms of diagnostic accuracy for ALN
metastasis. Of the 20 ALNs (8 metastasis, 12 benign) that showed
insufficient results on FNA cytology, FNA CYFRA 21-1 accuratelyyung Kim, MD, Ph oon, MD, PhD,
in Jung Kim, MD, PhD
indicate that FNA CYFRA 21-1, using an US-FNAB specimen, can be a
useful method equal to FNA cytology in terms of diagnostic accuracy.
(Medicine 94(19):e811)
Abbreviations: ALN = axillary lymph node, ALND= axillary lymph
node dissection, CK19 = cytokeratin 19, CYFRA 21-1 = cytokeratin
fragment 21-1, ER = estrogen receptor, FISH = fluorescent in situ
hybridization, FNACYFRA21-1=CYFRA21-1 concentrations from
US-FNAB specimens, FNA = fine needle aspirate, HER2 = human
epidermal growth factor receptor 2, IHC = immunohistochemical,
NPV = negative predictive value, OSNA = one-step nucleic acid
amplification, PR = progesterone receptor, SLNB = sentinel lymph
node biopsy, SLN = sentinel lymph node, US-FNAB = ultrasound-
guided fine-needle aspiration biopsy, US = ultrasound.
INTRODUCTION
A xillary lymph node (ALN) status is a most importantprognostic factor in breast cancer, and a large number of
metastatic ALNs are associated with poor prognosis.1,2 Sentinel
lymph node biopsy (SLNB) is a standard surgical procedure in
the axillary evaluation of patients presenting with invasive
breast cancer.3,4 This technique can decrease the morbidity
of axillary staging by preventing unnecessary axillary lymph
node dissection (ALND), which is linked to high morbidity.5,6
Sentinel lymph node (SLN) metastasis is usually determined by
hematoxylin and eosin-based frozen section or imprint
cytology; however, these intraoperative diagnostic methods
have low sensitivity and variation in protocols across institu-
tions.7,8 To overcome this issue, one-step nucleic acid ampli-
fication (OSNA), a rapid quantitative method for analyzing
cytokeratin 19 (CK19) mRNA expression, has been proposed as
a diagnostic method for SLNB by some researchers.9–13 On the
contrary, SLNB is an invasive surgical procedure involving the
risk of radiation exposure to the operating team and has high
associated costs and prolonged operation time.14 Therefore,
nonsurgical methods that can preoperatively determine ALN
status would be clinically beneficial to treatment decisions and
to reducing unnecessary SLNB.
For preoperative detection of ALN metastasis in breast
cancer, axillary ultrasound (US) and adjunctive ultrasound-
guided fine-needle aspiration biopsy (US-FNAB) for ultraso-
nographically suspicious ALNs are the most commonly used
methods.15–19 When patients have breast cancers and positive
results on US-guided fine needle aspirate (FNA) cytology of
ALN, surgeons can eliminate SLNB and advance directly to
ALND. In addition, preoperative diagnosis of ALN metastasisbe applicable to preoperative decision-
eatment options such as neoadjuvant
ast cancer patients. Also, axillary US
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combined with US-FNAB is a useful method for the early
detection of regional lymph node recurrence, which is associated
with poor prognosis in asymptomatic patients after breast cancer
surgery.20 However, researchers who examined the diagnostic
performance of axillary US combined with US-guided FNA
cytology have reported broad sensitivity ranges (21%–86%)
and negative predictive values (NPVs, 65%–90%).14–19,21 Con-
sequently, SLNB is performed to confirmALN status for patients
with negative or indeterminate results on FNA cytology. Given
this situation, some studies have reported that concentrations of
several tumor markers from US-FNAB ALN specimens may be
helpful for the preoperative diagnosis of ALN metastasis in
patients with breast cancer.22,23 Among the tumor markers
proposed, serum cytokeratin fragment 21-1 (CYFRA 21-1) is
a soluble fragment of CK19, which has been considered the most
appropriate marker due to its high expression in body fluids and
solid tumors of breast cancer patients.9,13,24,25 In a recent study,
the combination of FNA cytology and measuring CYFRA 21-1
concentrations from US-FNAB specimens (FNA CYFRA 21-1)
of ALN showed significantly higher performance than FNA
cytology alone in the diagnosis of ALN metastasis in breast
cancer patients.22 Moreover, the diagnostic accuracy of FNA
CYFRA 21-1 alone was comparable with that of FNA cytology
(91.7% vs. 89.1%, respectively). Therefore, we conducted this
study to externally validate FNA CYFRA 21-1 as a nonsurgical
method that can determineALNstatus in breast cancer patients.22
The purpose of this study was to compare the value of FNA
CYFRA 21-1 and FNA cytology and to assess whether FNA
CYFRA 21-1 is not inferior to FNA cytology in the diagnosis of
ALN metastasis in breast cancer patients.
MATERIALS AND METHODS
Study Population
This prospective study was approved by the institutional
review board of Severance Hospital, Yonsei University College
of Medicine, and written informed consent was obtained from
all patients. Between August 2010 and August 2014, 358 breast
cancer patients with 373 ALNs examined by US-FNAB were
consecutively enrolled in this study. In 343 patients, US-FNAB
was performed for one suspected ALN. Nine patients underwent
US-FNA of 2 ALNs located at different levels of the ipsilateral
axilla, and 5 patients underwent US-FNA of 1 ipsilateral and 1
contralateral ALN. One patient had bilateral cancers and under-
went US-FNA of bilateral ALNs.
Among the 358 patients, 254 patients (70.9%) had unilat-
eral breast surgery and ipsilateral SLNB or ALND. Among
these, 130 patients received neoadjuvant chemotherapy before
surgery. The remaining 104 patients (1 patient with bilateral
breast cancers and bilateral metastatic ALNs) did not undergo
operation due to the presence of distant metastasis (n¼ 68) or, in
postmastectomy patients, benign FNA cytology with improve-
ment or no change on follow-up imaging examination for 1
year (n¼ 36).
US and US-FNA of Axillary Lymph Nodes
AxillaryUSwas performed by 1 of 7 breast radiologistswith
different degrees of experience (2–13 years). The US systems
were Phillips ATL HDI, iU22 (Phillips-Advanced Technology
Laboratories, Bothell, WA, USA) machines equipped with high-
Choi et alfrequency linear transducers (5–12MHz). Bilateral axillae were
carefully examined in an orthogonal direction along the axillary
artery from the lower axilla to the junction of the axilla and
2 | www.md-journal.comupper arm. The US features of suspicious metastatic ALNs were
defined as the following: absence of fatty hilum, cortical thicken-
ing (>3mm), irregular or round shape,marked hypoechogenicity
of cortex, or increased peripheral blood flow on Doppler
US.23,26,27ALNs that showed one ormore suspicious US features
were considered suspicious, andUS-FNABwas performed for all
suspected metastatic ALNs.
US-FNAB was performed with a 23-gauge needle attached
to a 2-mL disposable syringe using freehand technique, and each
ALN was aspirated at least twice. Aspirated samples were
immediately expelled onto glass slides and smeared. All smears
were immediately fixed in 95% alcohol for Papanicolaou stain-
ing. The remaining aspirated materials in the needle and syringe
were rinsed with 1mL of saline, and then the washout was made.
The CYFRA 21-1 concentration was measured in the washout
samples. These procedures were performed on the same day.
FNA CYFRA 21-1 Analysis
CYFRA 21-1 concentrations in the FNAB washout speci-
mens of ALNs were measured by automated immunoanalyzer
system with chemiluminescent immunoassays (E411; Roche
Diagnostics, Germany). A noncompetitive immunometric sand-
wich assay format containing monoclonal antibody for CYFRA
21-1 was used with the immunoassay reagent.
Surgical Management of Axillary Lymph Nodes
Breast surgery including evaluation of the axillary nodal
status was performed by 1 of 4 breast surgeons with 9 to 24 years
of experience in breast surgery. ALNs with positive FNA
cytology underwent ALNDwithout SLNB. ALNs with negative
FNA cytology underwent SLNB, and according to these SLNB
results, ALND was performed on patients showing positive
histology on SLNB, while no further nodal dissection was done
if SLNB histology results were negative, except for patients
who underwent neoadjuvant chemotherapy. In addition, our
surgeons were aware of the size and location of the aspirated
ALNs described on preoperative US, and efforts were made to
find the correlating ALN at surgery.
Pathologic Analysis
Five cytopathologists (nonauthors with 1–15 years of
experience) interpreted the FNAB specimens of ALN. FNA
cytology results were divided into 2 categories. Reports of
metastasis from breast cancer or atypical cells were considered
positive. Reports of reactive hyperplasia or specific benign
diagnoses (eg, tuberculosis) were considered negative. Reports
of insufficient material were considered negative, because a
patient with insufficient material on FNA cytology should
undergo SLNB just like a patient with negative cytology.19,23,28
The reference standards for primary breast cancers were
the final histopathological results of surgical or core needle
biopsy specimens. The reference standards for ALNs were
surgical histopathological results (n¼ 254) or the combination
of FNA cytology results and clinical evidence during the follow-
up (n¼ 119).
Immunohistochemical (IHC) stains for estrogen receptor
(ER), progesterone receptor (PR), and human epidermal growth
factor receptor 2 (HER2) were performed on formalin-fixed,
paraffin-embedded tissue sections. In brief, 5-mm sections were
cut with a microtome, transferred onto adhesive slides, and
Medicine  Volume 94, Number 19, May 2015dried at 628C for 30 minutes. After incubation with primary
antibodies against ER (clone SP1, 1:100; Thermo Scientific,
Fremont, CA, USA), PR (clone PgR, 1:50; DAKO), or HER2
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21-1 to FNA cytology was established.
The diagnostic performances of the two methods were
compared according to IHC subtype of the corresponding(polyclonal, 1:1500; DAKO, Glostrup, Denmark), immunode-
tection was performed with biotinylated antimouse immuno-
globulin, followed by streptavidin-conjugated peroxidase from
a streptavidin biotin kit with 3,30-diaminobenzidine as the
chromogen substrate. A cutoff value of >1% positively stained
nuclei was used to determine ER- and PR-positivity.29 HER2
staining was scored in the range of 0 to 3þ, according to the
guidelines of the American Society of Clinical Oncology/Col-
lege of American Pathologists.30 Cases scored as 3þ were
considered HER2-positive, whereas cases scored as 0 to 1þ
were regarded as negative. Cases showing 2þ required further
examination using fluorescent in situ hybridization (FISH) to
measure HER2 amplification.HER2 gene/chromosome 17 ratio
of higher than 2.2 was considered HER2-positive by FISH.
Data and Statistical Analysis
Clinicopathologic data were gathered through review of
medical records. Clinicopathologic characteristics included size
of aspirated ALNs, status of ER, PR, and HER2 expression in
primary breast cancer, and presence of distant metastasis at the
time of diagnosis. Size of aspirated ALNs was measured as the
maximum diameter on either transverse or longitudinal scans of
preoperative US. Information on expression status of ER, PR,
and HER2 was determined based on the patients’ final patho-
logic reports. Primary breast cancers were grouped into luminal
(type A or B), HER2-enriched, or tripe negative cancers accord-
ing to IHC analysis.31,32
The Wilcoxon rank-sum test was used to compare the
median values of FNA CYFRA 21-1 between benign and
metastatic ALNs. In the analysis of diagnostic performance
of FNA CYFRA 21-1, ALN metastasis was determined using a
cutoff value of 1.93 ng/mL.22 The FNACYFRA 21-1 statuses of
ALNs were divided into 2 categories (negative or positive)
according to the FNA CYFRA 21-1 cutoff value. Sensitivity,
specificity, positive predictive value, NPV, and accuracy were
calculated based on reference standards for FNA cytology and
FNA CYFRA 21-1, respectively. These values of diagnostic
performances of FNA cytology and FNA CYFRA 21-1 were
compared using logistic regression with a generalized estimat-
ing equation. For testing noninferiority between FNA cytology
and FNA CYFRA 21-1, the noninferiority margin for the
difference in accuracies between FNA cytology and FNA
CYFRA 21-1 was set at 5% based on the differences in
accuracies of axillary US alone, axillary US combined with
US-guided FNA cytology or FNA CYFRA 21-1 in a previous
study.14,22 The sample size and 97.5% one-sided confidence
interval were calculated by Wald-type based statistics.
Additionally, the diagnostic performance of FNA CYFA 21-1
was compared with that of FNA cytology according to IHC
subtype of corresponding primary breast cancers. Statistical
analysis was performed with SAS for Windows, v. 9.0 (SAS
Institute, Cary, NC, USA). Two-sided P values <0.05 were
considered statistically significant. For the noninferiority test, a
one-sided P value of <0.025 was considered to indicate
statistical significance.
RESULTS
Clinicopathologic Patient Characteristics
The mean age of the patients was 49.5 years (range 27–83
Medicine  Volume 94, Number 19, May 2015years). The median size of aspirated ALNs was 12mm (inter-
quartile range 9–17mm). The number of each histologic type of
the primary breast cancers was 350 invasive ductal carcinomas
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.in 349 patients, 4 invasive lobular carcinomas in 4 patients,
2 mucinous carcinomas in 2 patients, 2 tubular carcinomas in
2 patients, and 1 neuroendocrine carcinoma in 1 patient. Among
the 263 cancers with available IHC analysis results, there were
197 luminal, 32 HER2-enriched type, and 34 triple negative
cancers. At final diagnosis, 237 (63.5%) of 373 ALNs were
positive for metastasis and 136 (36.5%) were negative. Distant
metastasis was observed in 69 cancers (19.2%) from 68 patients,
and the metastatic sites consisted of bone, lung, liver, brain, and
neck node, in order of frequency.
Diagnostic Performance of FNA CYFRA 21-1 and
FNA Cytology in Diagnosis of ALN Metastasis
The median value of FNA CYFRA 21-1 was significantly
higher in metastatic ALNs (93.3 ng/mL, interquartile range
6.7–500.0 ng/mL) compared with benign ALNs (0.7 ng/mL,
interquartile range 0.5–0.9 ng/mL) (P< 0.001) (Figure 1).
FNA cytology results from US-FNAB of 237 final meta-
static ALNs were positive for metastasis in 198, and negative in
39 nodes (31 benign and 8 insufficient) (Table 1). All 136 final
benign nodes had negative FNA cytology results (124 benign
and 12 insufficient). Of the 237 metastatic ALNs, 200 ALNs
had positive results (>1.93 ng/mL) by FNA CYFRA 21-1
analysis. Of the 20 ALNs (8 metastasis, 12 benign) that showed
insufficient results on FNA cytology, FNA CYFRA 21-1 accu-
rately diagnosed 15 ALNs (4 metastasis, 11 benign). The mean
value of 2 false-positive ALNs on FNA CYFRA 21-1 analysis
was 3.7 ng/mL (range 2.7–4.7 ng/mL).
Table 2 shows the diagnostic performance of FNACYFRA
21-1 and FNA cytology in the diagnosis of ALN metastasis.
There were no significant differences in the diagnostic per-
formance of FNA CYFRA 21-1 and FNA cytology (P> 0.05).
FNA CYFRA 21-1 and FNA cytology showed the same
accuracy of 89.5% for the diagnosis of ALN metastasis. In
testing for noninferiority, the lower boundary of the one-sided
97.5% confidence interval (0.027 to 1) lay above the pre-
defined noninferiority margin, and the P value was <0.025
(P< 0.001). Accordingly, the noninferiority of FNA CYFRA
CYFRA 21-1 in Node Metastasis of Breast CancerFIGURE 1. FNA CYFRA 21-1 of 373 axillary lymph nodes in 353
patients with invasive breast cancers. FNA CYFRA 21-1¼CYFRA
21-1 concentrations from US-FNAB specimens.
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TABLE 1. Correlation of FNA CYFRA 21-1 and FNA Cytology of 373 ALNs by Final ALN Diagnosis
FNA CYFRA 21-1 FNA Cytology
Final Diagnosis Positive (n¼ 202) Negative (n¼ 171) Positive (n¼ 198) Negative (n¼ 175)
Benign (n¼ 136) 2 (0.6) 134 (35.9) 0 (0.0) 136 (36.5)
Metastasis (n¼ 237) 200 (53.6) 37 (9.9) 198 (53.1) 39 (10.4)
RA 2
Choi et al Medicine  Volume 94, Number 19, May 2015primary breast cancers (Table 3). There were no significant
differences in the diagnostic performances of FNA CYFRA
21-1 and FNA cytology, according to IHC subtype of the
corresponding primary breast cancers.
DISCUSSION
CYFRA 21-1, the proteolytic part of CK19, can be
detected in serum and other body fluids, and elevated levels
of CYFRA 21-1 have been observed in various malignancies,
especially lung cancer.24,33,34 For breast cancer, a high level of
serum CYFRA 21-1 is significantly associated with advanced
stage or recurrent breast cancer, and has been proposed for use
in monitoring treatment response or disease relapse in breast
cancer patients.24,33,35,36 Moreover, a recent study reported that
CYFRA 21-1 concentrations in the US-FNAB specimens
obtained from metastatic ALNs can be helpful for the diagnosis
of ALNmetastasis in patients with breast cancer, as CYFRA 21-
1 concentrations of metastatic ALNs are significantly higher
than those of benign ALNs.22 In accordance with a previous
study, we confirmed that metastatic ALNs expressed signifi-
cantly higher FNA CYFRA 21-1 than benign ALNs. The values
of sensitivity (84.4%) and specificity (98.5%) as a diagnostic
marker of ALN metastasis were also similar to the values
previously reported.22
In the current study, FNA CYFRA 21-1 and FNA cytology
using the US-FNAB specimen did not significantly differ in
terms of their diagnostic performance for ALN metastasis in
breast cancer patients. These two methods showed the same
diagnostic accuracy (89.5%), and comparable sensitivity (83.5–
84.4%) and specificity (98.5–100%). Moreover, FNA CYFRA
21-1 reached statistical noninferiority to FNA cytology in terms
of diagnostic accuracy.
Non-numeric data are presented as the number of lymph nodes (percentage).
ALN¼ axillary lymph node, FNA¼fine needle aspirate, FNA CYFRA 21-1¼CYFWe additionally performed subgroup analysis according to
the IHC features of corresponding primary breast cancers,
because ER, PR, and HER2 status determined by IHC analysis
TABLE 2. Diagnostic Performance of FNA CYFRA 21-1 and
FNA Cytology in Predicting Metastatic ALN
Diagnostic
Method
FNA CYFRA
21-1
FNA
Cytology P
Sensitivity 84.4 (79.7, 88.3) 83.5 (78.8, 88.3) 0.683
Specificity 98.5 (96.5, 100) 100.0 (100.0, 100.0) 0.157
PPV 99.0 (97.6, 100) 100.0 (100.0, 100.0) 0.155
NPV 78.3 (72.2, 84.5) 77.7 (71.6, 83.9) 0.769
Accuracy 89.5 (86.4, 92.7) 89.5 (86.4, 92.7) –
Data are presented as percentages (95% confidence interval).
ALN¼ axillary lymph node, FNA¼fine needle aspirate, FNA CYFRA 21-
1¼CYFRA 21-1 concentrations fromUS-FNAB specimens, NPV¼ negative predictive
value, PPV¼ positive predictive value.
4 | www.md-journal.comare currently used for breast cancer subtype classifi-
cation.10,31,32 The diagnostic performance of FNA CYFRA
21-1 was not significantly different from that of FNA cytology
in the subgroups classified by IHC subtype of primary breast
cancers. Our overall results indicate that FNA CYFRA 21-1 can
be applied to all breast cancer patients regardless of their cancer
subtypes as a substitute for FNA cytology. In addition, our
results are in accordance with those from previous studies,
which found that the CK19 expression rate was as high as
98.4% in breast adenocarcinoma,11,37 whereas a smaller group
of breast cancer with basal-like subtype expressed CK5/6,
CK14, and CK17.38,39 That is the same reason why CK-19 is
used as a diagnostic marker in OSNA for the detection of
metastases in SLNs of breast cancer.9–13
FNA CYFRA 21-1 has the primary advantage of enabling
preoperative or pretreatment diagnosis of ALN metastasis,
because it also uses US-FNAB specimens like FNA cytology.
Therefore, FNA CYFRA 21-1 can be an equally useful method
for breast cancer patients who are considering neoadjuvant
chemotherapy prior to surgery or who have suspected metastatic
ALNs on postoperative follow-up imaging study. In addition to
diagnostic performance, FNA CYFRA 21-1 has strong clinical
advantages compared with FNA cytology. FNA cytology may
provide subjective results that may differ from one pathologist
to another, and insufficient results that require additional test-
ing, such as repeated FNA or surgical biopsy. However, FNA
CYFRA 21-1 can provide objective results using a cutoff value,
and may enhance the diagnostic value of US-FNAB in cases
with insufficient results on FNA cytology. Among the 20 ALNs
(8 metastatic, 12 benign) with insufficient FNA cytology results
of this study, 15 ALNs (4metastatic, 11 benign) were accurately
diagnosed by FNA CYFRA 21-1. On the contrary, FNA
cytology interpretation is time-consuming, and may take sev-
eral days to provide definitive results according to the cytol-
ogists’ schedule. In comparison, measuring FNA CYFRA 21-1
takes a relatively short time as long as the equipment for the
evaluation of CYFRA 21-1 is available. Consequently, FNA
CYFRA 21-1 using US-FNAB specimens may be more useful
than FNA cytology for the diagnosis of ALN metastasis, due to
strong clinical advantages and comparable diagnostic perform-
ance to FNA cytology.
Our study had several limitations. First, we used a cutoff
value of 1.93 ng/mL, determined by previous preliminary
study,22 to assess the diagnostic performance of FNA CYFRA
21-1. Although diagnostic performance of FNA CYFRA 21-1
was as good as that of FNA cytology, there were two false-
positive ALNs with FNA CYFRA 21-1, but no false-positives
with FNA cytology in this study. Accordingly, further study
with a larger number of patients is needed to determine the best
1-1 concentrations from US-FNAB specimens.cutoff value of FNA CYFRA 21-1 in the diagnosis of ALN
metastasis from breast cancer. Second, we cannot estimate the
cost of each FNA CYFRA 21-1 test, because this is a
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.preliminary study. Therefore, cost-effectiveness analysis of this
method may be needed in the future. Third, we cannot entirely
rule out the possibility that the aspirated ALN was not the SLN
for patients who only underwent SLNB. However, we believe
that this limitation is inevitable because routine ALND is not
currently recommended in breast cancer patients. Also, we think
that our method of surgical management for ALNs may not
have much effect on our results, because the purpose of this
study was to assess whether FNA CYFRA 21-1 is not inferior to
FNA cytology in the diagnosis of ALN metastasis in breast
cancer patients. Fourth, we did not evaluate the association
between the FNA CYFRA 21-1 value and tumor burden of
aspirated metastatic ALN or nonaspirated, but surrounding
metastatic, ALN. According to the American College of Sur-
geons Oncology Group Z0011 randomized trial, SLN dissection
alone did not result in inferior survival compared with ALND
among patients with limited SLN metastatic breast cancer
treated with breast conservation surgery, radiation, and
systemic therapy.40 Under these circumstances, if the FNA
CYFRA 21-1 values correlate with nodal tumor burden or
number of metastatic ALNs, they may be useful not only in
the diagnosis of ALN metastasis, but also in determining the
appropriate surgical procedure for ALN metastasis. Accord-
ingly, further study is needed to evaluate the utility of FNA
CYFRA 21-1 in predicting advanced nodal stage.
In conclusion, the diagnostic performance of FNACYFRA
21-1 is comparable to that of FNA cytology for the diagnosis of
ALN metastasis in breast cancer patients. Our results indicate
that FNA CYFRA 21-1 using an US-FNAB specimen can be a
novel and useful method that is as good as FNA cytology in
terms of diagnostic accuracy.
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